We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Hookipa Pharma Inc
36 own
72 watching
Current Price
$1
$0.03
(2.99%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
54.72M
52-Week High
3.05
52-Week Low
0.72
Average Volume
0.21M
Dividend Yield
--
P/E Ratio
115.2084
Market Capitalization54.72M52-Week High3.0552-Week Low0.72Average Volume0.21MDividend Yield--P/E Ratio115.2084What does the Hookipa Pharma Inc do?
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.
Read More
How much money does Hookipa Pharma Inc make?
News & Events about Hookipa Pharma Inc.
Globe Newswire
6 months ago
Novel arenaviral immunotherapy is directed against the prostate cancer targets PAP and PSA; Phase 1/2 trial to commence by early 2023Drug Master File (DMF) accepted to support future FDA submissions NEW YORK and VIENNA, Austria, July 25, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ...
Globe Newswire
7 months ago
NEW YORK and VIENNA, Austria, June 21, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced several leadership changes as the company expands its clinical development...
Globe Newswire
7 months ago
Alternating 2-vector therapy showed superior antigen-specific T cell responses, more robust anti-tumor activity and similar tolerability vs. single-vector therapyPhase 2 to proceed with alternating 2-vector therapy in combination with pembrolizumab, which will help inform the randomized Phase 2 ...
Frequently Asked Questions
Frequently Asked Questions
What is Hookipa Pharma Inc share price today?
Can Indians buy Hookipa Pharma Inc shares?
How can I buy Hookipa Pharma Inc shares from India?
Can Fractional shares of Hookipa Pharma Inc be purchased?
What are the documents required to start investing in Hookipa Pharma Inc stocks?
What is today’s traded volume of Hookipa Pharma Inc?
What is today’s market capitalisation of Hookipa Pharma Inc?
What is the 52-Week High and Low Range of Hookipa Pharma Inc?
What percentage is Hookipa Pharma Inc down from its 52-Week High?
What percentage is Hookipa Pharma Inc up from its 52-Week Low?
Current Price
$1
$0.03
(2.99%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.